Does religious faith lead to greater rewards here on Earth?

Delayed gratification: People who are good at overcoming their immediate impulses to take small rewards now — in favor of larger rewards down the road — do better in many areas of life, including academic achievement, income, job performance and health. What life experiences develop this ability? A new study published online, ahead of print, by the journal of Evolution and Human Behavior, finds that religious people are better able to forgo immediate satisfaction in order to gain larger rewards in the future. The study is the first to demonstrate an association between religious commitment and a stronger preference for delayed, but more significant, rewards. 

"It's possible to analyze virtually all contemporary social concerns, from excessive credit card debt to obesity, as problems of impulsivity. So the fact that religious people tend to be less impulsive has implications for the sorts of decisions they make with their money, time, and other resources," says Michael McCullough, professor of Psychology in the College of Arts and Sciences at the University of Miami (UM), and principal investigator of this study. "Their tendency toward less impulsive decision-making might even be relevant to their stands on public policy issues, such as whether governments should be seeking to reduce their expenditures on public services and entitlement programs in the current economic environment." 

In the research work, titled "Religious people discount the future less," 277 undergraduate University students, from a variety of religious denominations and ethnic backgrounds, chose between receiving a small financial monetary reward that the investigators made available immediately--for example "$50 today," or a larger reward that was available only after longer amounts of time had passed—for example, "$100 six months from now." Participants' commitment to their religious beliefs and institutions was also measured, among other relevant variables. The data shows that the extent to which the participants follow religious teachings positively correlates with their ability to delay gratification. 

The findings suggest that through religious beliefs and practices, people "develop a more patient style of decision making." According to the study, religion teaches this type of patience by directing people's attention to the distant future—the afterlife—which may cause their nearer-term future on this earth to feel subjectively closer. 

"People who are intrinsically religious and who indicate an interest in the afterlife tend to report that the future feels as though it is approaching quickly and that they spend a lot of time thinking about the future," the study says. 

Source: University of Miami [April 04, 2012]

Read more »

Keep aging brains sharp

Exercising, eating a healthy diet and playing brain games may help you keep your wits about you well into your 80s and even 90s, advises a new book by researchers at George Mason University. 

"These are all cheap, easy things to do," says Pamela Greenwood, an associate professor in the Department of Psychology on Mason's Fairfax, Va. campus. "We should all be doing them anyway. You should do them for your heart and health, so why not do them for your brain as well?" 

For the past 20 years, Greenwood and Raja Parasuraman, University Professor of Psychology, have studied how the mind and brain age, focusing on Alzheimer's disease. Their book, "Nurturing the Older Brain and Mind" published by MIT Press, came out in March. The cognitive neuroscientists geared the book to middle-aged readers who want to keep their mental snap. 

"We know that if we can put off dementing illnesses even by a year or two through lifestyle changes, that will reduce the number of people with Alzheimer's disease, which is reaching epidemic proportions," Parasuraman says. 

Not everyone's brain declines when retirement age hits. "You can look at a group of 65-year-olds — some are in nursing homes, and some are running the world," Greenwood says. 

Now that more workers are staying on the job longer for economic reasons and because countries are upping the retirement age, keeping the mind agile becomes paramount, Parasuraman says. 

For the book, Parasuraman and Greenwood examined only scientific studies, theirs and others, ranging from neurological to physiological. A few surprises leaped out of the data. 

"Several old dogmas were overturned," Parasuraman says. "There's the tired old joke that we're losing brain cells as we age — maybe starting as young as 20 or 30 — and it's all downhill after that." 

Not so, new research reveals. Not only are some 60-year-olds as sharp as 20-year-olds, but their brains still create new cells. Brain cells may not grow as fast as bone or skin cells, but grow they do, particularly in the hippocampus. "It's the area of the brain that's very important to memory and is affected by Alzheimer's disease," Parasuraman says. 

Novel experiences and new learning help new brain cells become part of the circuitry. Parasuraman points to a study of terminally ill cancer patients whose brains were still forming new neurons. "If a person who's in a terminally ill state can generate new neurons, then surely healthy people can," Parasuraman says. 

Brain games and new experiences may build up "white matter," which insulates neurons as they carry signals, Greenwood says. In older brains, this white matter insulation develops holes and signals go awry. 

Older adult gamers are winning skills to help them move through life, Parasuraman says. "We are looking at everyday problem solving," he says. "Are you better at balancing a checkbook? Are you better at making decisions in a grocery store? We're finding you get better at those tasks (after playing the video games in the study)." 

Moving large muscle groups also builds brain matter. In one study detailed in the book, older, sedentary people began walking or did stretching exercises for 45 minutes, three times a week. "Those people actually became smarter over time," Greenwood says. "You don't have to be running Ironman marathons. You can just walk briskly three or four times a week." 

Another best bet for an active mind is a nutritious diet that limits calories to the minimum amount needed to keep a body healthy. No starvation diets, though. "The strongest evidence we have is not very pleasant, which is dietary restriction, reducing calories," Parasuraman says. "That clearly improves longevity and cognition. The evidence in animals is very strong. Such dietary restriction may never be popular. But perhaps every-other-day fasting as an approximation to it is something people would tolerate: You eat normally one day, and the next day you don't." 

Popping supplements won't fill a nutritionally deficient diet, Parasuraman says. "A lot of people think, 'I can eat junk food and then take a pill.' No. You have to eat fruits and vegetables, leafy vegetables. It has to be part of the regular diet because otherwise it's not absorbed." 

Fat cells help make up cell membranes. The unsaturated fats found in fish and olive oils may boost flexibility in these membranes. The more flexible membranes are, the better they may work, scientists theorize. Saturated fats such as butter have to go because these fats vie with healthy fats for a place in the cell membrane, Greenwood explains. 

Greenwood and Parasuraman want people to know that getting old doesn't mean getting senile. "The bottom line message of the book is really a hopeful one," Greenwood says. "There are lots of things that you can do (to keep your brain healthy)." 

Source: George Mason University [April 04, 2012]

Read more »

Death anxiety increases atheists' unconscious belief in God

New research suggests that when non-religious people think about their own death they become more consciously skeptical about religion, but unconsciously grow more receptive to religious belief. 

The research, from the Department of Psychology at the University of Otago in New Zealand, also found that when religious people think about death, their religious beliefs appear to strengthen at both conscious and unconscious levels. The researchers believe the findings help explain why religion is such a durable feature of human society. 

In three studies, which involved 265 university students in total, religious and non-religious participants were randomly assigned to "death priming" and control groups. Priming involved asking participants to write about their own death or, in the control condition, about watching TV. 

In the first study, researchers found that death-primed religious participants consciously reported greater belief in religious entities than similar participants who had not been death-primed. Non-religious participants who had been primed showed the opposite effect: they reported greater disbelief than their fellow non-religious participants in the control condition. 

Study co-author Associate Professor Jamin Halberstadt says these results fit with the theory that fear of death prompts people to defend their own worldview, regardless of whether it is a religious or non-religious one. 

"However, when we studied people's unconscious beliefs in the two later experiments, a different picture emerged. While death-priming made religious participants more certain about the reality of religious entities, non-religious participants showed less confidence in their disbelief," Associate Professor Halberstadt says. 

The techniques used to study unconscious beliefs include measuring the speed with which participants can affirm or deny the existence of God and other religious entities. After being primed by thoughts of death, religious participants were faster to press a button to affirm God's existence, but non-religious participants were slower to press a button denying God's existence. 

"These findings may help solve part of the puzzle of why religion is such a persistent and pervasive feature of society. Fear of death is a near-universal human experience and religious beliefs are suspected to play an important psychological role in warding off this anxiety. As we now show, these beliefs operate at both a conscious and unconscious level, allowing even avowed atheists to unconsciously take advantage of them." 

The paper co-authors also included Jonathan Jong, currently at the University of Oxford, who undertook the experiments as part of his PhD thesis, and Matthias Bluemke, currently at the University of Heidelberg. Associate Professor Halberstadt was Jong's supervisor. 

The findings from the three experiments will be published in the Journal of Experimental Social Psychology. 

Source: University of Otago [April 01, 2012]

Read more »

DNA sequencing lays foundation for personalized cancer treatment

Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor – considered key to personalizing cancer treatment – but to map the genetic evolution of disease and monitor response to treatment. 

The Genomics of Drug Sensitivity in Cancer project released its first results on July 15th. Researchers released a first dataset from a study that will expose 1,000 cancer cell lines (including ovarian) to 400 anticancer treatments [Washington University]

"We're finding clinically relevant information in the tumor samples we're sequencing for discovery-oriented research studies," says Elaine Mardis, PhD, co-director of The Genome Institute at the School of Medicine. "Genome analysis can play a role at multiple time points during a patient's treatment, to identify 'driver' mutations in the tumor genome and to determine whether cells carrying those mutations have been eliminated by treatment." 

This work is helping to guide the design of future cancer clinical trials in which treatment decisions are based on results of sequencing, says Mardis, who is speaking April 1 at the opening plenary session of the American Association for Cancer Research annual meeting in Chicago. She also is affiliated with the Siteman Cancer Center at the School of Medicine and Barnes-Jewish Hospital. 

To date, Mardis and her colleagues have sequenced all the DNA – the genome – of tumor cells from more than 700 cancer patients. By comparing the genetic sequences in the tumor cells to healthy cells from the same patient, they can identify mutations underlying each patient's cancer. 

Already, information gleaned through whole-genome sequencing is pushing researchers to reclassify tumors based on their genetic makeup rather than their location in the body. In patients with breast cancer, for example, Mardis and her colleagues have found numerous driver mutations in genes that have not previously been associated with breast tumors. 

A number of these genes have been identified in prostate, colorectal, lung or skin cancer, as well as leukemia and other cancers. Drugs that target mutations in these genes, including imatinib, ruxolitinib and sunitinib, while not approved for breast cancer, are already on the market for other cancers. 

"We are finding genetic mutations in multiple tumor types that could potentially be targeted with drugs that are already available," Mardis says. 

She predicts, however, that it may require a paradigm change for oncologists to evaluate the potential benefits of individualized cancer therapy. While clinical trials typically involve randomly assigning patients to a particular treatment regimen, a personalized medicine approach calls for choosing drugs based on the underlying mutations in each patient's tumor. 

"Having all treatment options available for every patient doesn't fit neatly into the confines of a carefully designed clinical trial," Mardis acknowledges. "We're going to need more flexibility." 

When during the course of cancer mutations develop also is likely to be important in decisions about treatment. In a recent study, Mardis and her team mapped the genetic evolution of leukemia and found clues to suggest that targeted cancer drugs should be aimed at mutations that develop early in the course of the disease. 

Using "deep digital sequencing," a technique developed at The Genome Institute, they sequenced individual mutations in patients' tumor samples more than 1,000 times each. This provides a read-out of the frequency of each mutation in a patient's tumor genome and allowed the researchers to map the genetic evolution of cancer cells as the disease progressed. 

They found that as cancer evolves, tumors acquire new mutations but always retain the original cluster of mutations that made the cells cancerous in the first place. Their discovery suggests that drugs targeted to cancer may be more effective if they are directed toward genetic changes that occur early in the course of cancer. Drugs that target mutations found exclusively in later-evolving cancer cells likely may not have much effect on the disease because they would not kill all the tumor cells. 

Mardis says that sequencing the entire genome of cancer cells is essential to piecing together an accurate picture of the way cancer cells evolve. If the researchers had sequenced only the small portion of the genome that involves genes, they would not have had the statistical power to track the frequency of mutations over time. (Only 1 to 2 percent of the genome consists of genes.) 

In another study, a phase III clinical trial of post-menopausal women with estrogen-receptor positive breast cancer, the Washington University researchers have shown that sequencing can help to predict which women will respond to treatment with aromatase inhibitors. These estrogen-lowering drugs are often prescribed to shrink breast tumors before surgery. But only about half of women with estrogen-receptor positive breast cancer respond to these drugs, and doctors have not been able to predict which patients will benefit. 

Interestingly, by sequencing patients' breast tumors before and after aromatase inhibitor therapy, the researchers identified substantive genomic changes that had occurred in responsive patients, whereas the genomes of unresponsive patients remained largely unchanged by the therapy. 

"No one has ever looked at treatment response at this level of resolution," Mardis says. "It's so obvious who is responding." 

In addition, the researchers have identified a series of mutations in the breast tumors that have corresponding small-molecule inhibitor drugs that target defective proteins. This finding indicates that for women who are not responding to aromatase inhibitors, treatment options may include combining conventional chemotherapy with the indicated small-molecule inhibitor. 

"We felt it was important to show there could be therapeutic options available to patients who are resistant to aromatase inhibitors," Mardis says. "As we move forward, we think sequencing will contribute crucial information to determining the best treatment options for patients."  

Source: Washington University School of Medicine [April 01, 2012]

Read more »